A Phase 2 interventional study of Leuprolide acetate depot (LAD) 11.25 mg 3 Month and Matched placebo in Hodgkin Disease, Lymphoma, Non-Hodgkin and Multiple Myeloma, sponsored by Abbott. Terminated at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-05-06.
Sponsored by Abbott · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.
Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 503rd largest by enrollment of the 818 interventional ones that give a count, is one of 45 that started in 2006, is one of 346 in phase 2, and was the 266th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
M.D. Anderson Cancer Center · Sites in United States
Ages 2–21
Michael Spinner, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
970 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 389 · Phase 2 460 · Phase 3 57 · Phase 4 1
First in 1988; this study’s year is marked. 45 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 35 across the 818 interventional studies, 111 across the 80 observational. Of the 779 that completed or were terminated, 326 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
137 of 970 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 2 studies filed under Hodgkin Disease — fewer than ten, so there is no comparison to draw.
49 of the studies in Hodgkin Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01483664Memorial Sloan Kettering Cancer CenterCommunication Skills Intervention to Promote Transition Into Survivorship | 2026-11 |
| NCT03681561Veronika BachanovaNivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | 2026-11 |
| NCT06923397Dana-Farber Cancer InstituteInterrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | 2026-11-28 |
| NCT05723055University of UtahEvaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2026-12 |
| NCT06150664Compass TherapeuticsA Phase 1 of CTX-8371 in Patients With Advanced Malignancies | 2026-12 |
Add all 49 to your calendar (.ics) → With an account.
Among the 970 studies in Hodgkin Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
This Phase 2 study will be conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation. Patients will be randomized to receive either LAD 11.25 mg 3 Month treatment or placebo and all patients will be vaccinated with KLH 6 months posttransplant. Patients will be evaluated to determine if the rate of immunologic recovery in the LAD group is enhanced compared with the placebo group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma and be considered an appropriate candidate for hematopoietic stem cell transplant.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three intramuscular injections LAD 11.25 mg 3 Month treatment administered approximately 3 months apart.
Drug: Leuprolide acetate depot (LAD) 11.25 mg 3 Month
Three intramuscular injections of matched placebo administered approximately 3 months apart.
Drug: Matched placebo
LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
Also known as: Lupron
Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
Mean Change From Baseline in IgM Response (Mcg/mL) Before Keyhole Limpet Hemocyanin (KLH) Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo
Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Serum immunoglobulin IgM antibodies were determined by enzyme-linked immunosorbent assay (ELISA). Baseline is defined as the IgM concentration before the KLH vaccination. Change from baseline was calculated as the IgM value postvaccination minus the IgM value at prevaccination.
Time frame: Month 6 prevaccination (baseline) and Month 7 postvaccination
Mean Change From Baseline in IgG1 Response (Mcg/mL) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo
Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Serum immunoglobulin IgG1 antibodies were determined by enzyme-linked immunosorbent assay (ELISA). Baseline is defined as the IgG1 concentration before the KLH vaccination. Change from baseline was calculated as the IgG1 value postvaccination minus the IgG1 value at baseline.
Time frame: Month 6 prevaccination (baseline) and Month 7 postvaccination
Mean Change From Baseline in Interferon Gamma Response (Spots/1 Million Cells) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo
Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Interferon gamma was determined by enzyme-linked immunosorbent spot-forming cell (ELISpot). Baseline is defined as the interferon gamma concentration obtained before the KLH vaccination. Change from baseline was calculated as the interferon gamma value postvaccination minus the interferon gamma value at baseline.
Time frame: Month 6 prevaccination (baseline) and Month 7 postvaccination
Mean Change From Baseline in T Cell Excision Circles (TREC) Per 100,000 CD4+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant
CD4+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD4 cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD4+ cells minus pretransplant TREC /100,000 CD4+ cells.
Time frame: Pretransplant and posttransplant (Month 12)
Mean Change From Baseline in TREC Per 100,000 CD8+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant
CD8+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD8+ cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD8+ cells minus pretransplant TREC /100,000 CD8+ cells.
Time frame: Pretransplant and posttransplant (Month 12)
| Milestone | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo |
|---|---|---|
| Started | 12 | 13 |
| Completed | 6 | 4 |
| Not completed | 6 | 9 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Disease progression | 2 | 5 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Started chemotherapy | 1 | 0 |
Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Serum immunoglobulin IgM antibodies were determined by enzyme-linked immunosorbent assay (ELISA). Baseline is defined as the IgM concentration before the KLH vaccination. Change from baseline was calculated as the IgM value postvaccination minus the IgM value at prevaccination.
| mcg/mL | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo |
|---|---|---|
| Mean IgM at baseline (mcg/mL) | 4.0 ± 3.8 | 3.0 ± 2.8 |
| Mean IgM change from baseline (mcg/mL) | 2.91 ± 2.07 | 0.57 ± 0.83 |
CD4+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD4 cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD4+ cells minus pretransplant TREC /100,000 CD4+ cells.
| TREC /100,000 CD4+ cells | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo |
|---|---|---|
| Baseline TREC per 100,000 CD4+ cells | 67.524 ± 47.0863 | 173.712 ± 206.1733 |
| Mean change in TREC from baseline to final visit | 522.321 ± 920.790 | -63.950 ± 235.561 |
CD8+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD8+ cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD8+ cells minus pretransplant TREC /100,000 CD8+ cells.
| TREC /100,000 CD8+ cells | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo |
|---|---|---|
| Baseline mean for TREC per 100,000 CD8+ cells | 181.673 ± 209.7599 | 364.414 ± 280.3465 |
| Mean change in TREC from baseline to final visit | -10.811 ± 343.061 | -184.084 ± 282.405 |
Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Serum immunoglobulin IgG1 antibodies were determined by enzyme-linked immunosorbent assay (ELISA). Baseline is defined as the IgG1 concentration before the KLH vaccination. Change from baseline was calculated as the IgG1 value postvaccination minus the IgG1 value at baseline.
| mcg/mL | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo |
|---|---|---|
| Mean IgG1 at baseline (mcg/mL) | 8.6 ± 9.1 | 10.8 ± 11.6 |
| Mean IgG1 change from baseline (mcg/mL) | 46.16 ± 44.01 | 16.76 ± 28.15 |
Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Interferon gamma was determined by enzyme-linked immunosorbent spot-forming cell (ELISpot). Baseline is defined as the interferon gamma concentration obtained before the KLH vaccination. Change from baseline was calculated as the interferon gamma value postvaccination minus the interferon gamma value at baseline.
| spots/1 million cells | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo |
|---|---|---|
| Mean interferon gamma at baseline | 0.2 ± 3.2 | -1.4 ± 3.2 |
| Mean interferon gamma change from baseline | 2.09 ± 4.85 | 10.25 ± 11.41 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | — | 6/12 (50%) | 7/12 (58.3%) |
| Placebo | — | 4/13 (30.8%) | 7/13 (53.8%) |
| Event | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/12 | 1/13 |
| PyrexiaGeneral disorders | 1/12 | 0/13 |
| GastroenteritisInfections and infestations | 1/12 | 0/13 |
| Pneumonia mycoplasmalInfections and infestations | 1/12 | 0/13 |
| Respiratory tract infection bacterialInfections and infestations | 1/12 | 0/13 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/12 | 0/13 |
| Deep vein thrombosisVascular disorders | 1/12 | 0/13 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/12 | 1/13 |
| PneumoniaInfections and infestations | 0/12 | 1/13 |
| Respiratory tract infection viralInfections and infestations | 0/12 | 1/13 |
| Event | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo |
|---|---|---|
| PyrexiaGeneral disorders | 0/12 | 2/13 |
| Back painMusculoskeletal and connective tissue disorders | 0/12 | 2/13 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/12 | 2/13 |
| PalpitationsCardiac disorders | 1/12 | 0/13 |
| HypogonadismEndocrine disorders | 1/12 | 0/13 |
| Food poisoningGastrointestinal disorders | 1/12 | 0/13 |
| Injection site swellingGeneral disorders | 1/12 | 0/13 |
| Herpes zosterInfections and infestations | 1/12 | 0/13 |
| Urinary tract infectionInfections and infestations | 1/12 | 0/13 |
| Blood creatinine increasedInvestigations | 1/12 | 1/13 |
| Age, Categorical(Participants) | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 13 | 25 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo | Total |
|---|---|---|---|
| Mean | 49.0 ± 10.16 | 47.4 ± 7.04 | 48.2 ± 8.53 |
| Sex: Female, Male(Participants) | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 9 | 10 | 19 |
| Region of Enrollment(participants) | Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month | Placebo | Total |
|---|---|---|---|
| United States | 12 | 13 | 25 |
The record gives a start of Feb 2006 and a primary completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide